FDAnews Drug Daily Bulletin
July 13, 2012 | Vol. 9 No. 137
Companies manufacturing and distributing unapproved oxycodone products have 45 days to stop producing the pain meds and 90 days to cease shipping them or risk ramped up FDA enforcement.
Devising strategies to engage physicians, teaching hospitals and medical societies will be critical to implementing a successful Sunshine Act compliance program, healthcare compliance expert Michaeline Daboul says.
The House has passed H.R. 4223, the SAFE Doses Act, by voice vote, taking another step toward ramped-up penalties for medical product thefts.
Scientists found a way to use the body’s natural clot-producing mechanisms to deliver targeted medicine in a study that may have implications for treatments of heart attacks and stroke.
When all else failed, the promise of corporate profits for pediatric cancer drugs did what cajoling to save children could not.
India is proposing an ambitious plan to substantially increase spending by providing free drugs for India’s 1.2 billion population.
SPI subsidiary Sucampo Pharmaceuticals has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a prescription drug for the treatment of chronic constipation, excluding constipation caused by organic diseases.
The CEO of one of the world’s biggest pharmaceutical giants says he is confident about Ireland’s future and points to the “quality” and “work ethic” of its young college grads as a key reason for that belief.
Amgen has finalised its $315 million (202.63 million pounds) acquisition of KAI Pharmaceuticals, as originally announced in April 2012.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.